Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of British Columbia

$25,000.00

Synthesis of a pharmaceutical product

EF 2017-18

Résumé
ME Therapeutics, a Canadian pharmaceutical company located in Vancouver, BC, requires two anticancercompounds that are not available commercially and can only be produced by chemical synthesis. METherapeutics wishes to collaborate with the Applicant, a World-renowned synthetic organic chemist, to preparethe requisite materials.
Programme
Engage Grants Program
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
522345-2017
Name nom
Ciufolini, Marco
Department département
Chemistry
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1100
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Health, education and social services
Area of application fr
Santé publique, éducation et services sociaux
Research subject code
3703
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic syntheses
Research subject fr
Synthèses organiques
Partie
1
Nb partie
1
Application title
Synthesis of a pharmaceutical product
Keyword
NSERC
Application summary
ME Therapeutics, a Canadian pharmaceutical company located in Vancouver, BC, requires two anticancercompounds that are not available commercially and can only be produced by chemical synthesis. METherapeutics wishes to collaborate with the Applicant, a World-renowned synthetic organic chemist, to preparethe requisite materials.